Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mosunetuzumab + lenalidomide versus anti-CD20 antibody plus chemotherapy in previously untreated high-tumor-burden follicular lymphoma
jRCT2011240017Phase 3Active, not recruiting
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- Nov 2024
- Modality
- Small Molecules, T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of mosunetuzumab and lenalidomide in follicular lymphoma (FL) (2 arms), sponsored by Chugai Pharmaceutical Co., Ltd. Primary endpoint: Primary efficacy endpoint. Started Nov 2024; status: active, not recruiting.
02
Drugs
mosunetuzumablenalidomide
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on jRCT2011240017.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2011240017.